IP Library Granted Patent US 12687553
Granted Patent B2
US 12687553 · App. 17/760,021 · Granted Jul 21, 2026

Method for capturing and identifying cellular agglutinates for detecting multiplex anti-erythrocyte antibodies

Inventors: Pauline Follet (Rexpoede, FR); Pierre Lebrun (Meurchin, FR); Christophe Olivier (Libercourt, FR); David Poirier (Laval, FR); Vianney Souplet (Quesnoy sur Deule, FR)
Assignee: INNOBIOCHIPS
G01N33/80G01N33/577G01N2400/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12687553
App. No.
17/760,021
Granted
Jul 21, 2026
Kind
B2
Abstract

The present invention relates to an in-vitro method for detecting anti-erythrocyte antibodies in a sample, comprising at least the following steps: a) bringing the sample into contact with one or more test erythrocytes or a suspension of one or more test erythrocytes having a known phenotype, under conditions likely to induce hemagglutination, so as to obtain a reaction mixture; b) bringing the reaction mixture into contact with a solid substrate containing a plurality of defined adsorption areas which have previously fixed antibodies or antibody fragments capable of binding antigenic determinants present on the one or more test erythrocytes; c) ascertaining the presence or absence of a hemagglutination reaction in at least one of the adsorption areas so as to detect the presence or absence of anti-erythrocyte antibodies in the sample; the steps a) and b) being carried out separately or simultaneously.

Claims (21)

1 . An in vitro method for detecting anti-erythrocyte antibodies in a sample, comprising at least the following steps:

a) bringing said sample containing anti-erythrocyte antibodies into contact with one or more test erythrocyte(s) or a suspension of test erythrocyte(s) of known phenotype, under conditions capable of inducing hemagglutination, so as to obtain a reaction mixture;

b) bringing said reaction mixture into contact with a solid support containing a plurality of defined adsorption zones which have previously bonded antibodies or antibody fragments capable of binding antigenic determinants present on said test erythrocyte(s), wherein at least two of the adsorption zones each bond a plurality of antibodies and/or antibody fragment(s) capable of binding a distinct erythrocyte antigenic determinant;

c) determining the presence or absence of a hemagglutination reaction on at least one of said adsorption zones, wherein the presence of a hemagglutination reaction indicates the presence of anti-erythrocyte antibodies from the sample which recognize the same antigenic determinants recognized by the previously bonded antibodies or antibody fragments and wherein the absence of a hemagglutination reaction indicates the absence of anti-erythrocyte antibodies from the sample which recognize the same antigenic determinants recognized by the previously bonded antibodies or antibody fragments;

said steps a) and b) being carried out separately or simultaneously.

2 . The in vitro detection method as claimed in claim 1 , wherein said anti-erythrocyte antibodies to be detected are capable of specifically binding antigenic determinants chosen from the following systems or antigens: ABO, Rhesus, Kell, MNS, P, Lutheran, lewis, Duffy, Kidd, Diego, Cartwright, Xg, Scianna, Dombrock, Colton, Landsteiner-Wiener, Chido/Rodgers, Hh, Kx, Gerbich, Cromer, Knops, Indian, OK, RAPH, John Milton Hagen, Li, Globoside, GIL, Rh-associated glycoprotein, Forssmann, JR, LAN, VEL, CD59.

3 . The in vitro detection method as claimed in claim 1 , wherein said anti-erythrocyte antibodies to be detected are capable of specifically binding antigenic determinants of the ABO system.

4 . The in vitro detection method as claimed in claim 1 , wherein said antibodies or antibody fragments of the adsorption zone are monoclonal or polyclonal antibodies chosen from: anti-A antibodies (ABO1), anti-B antibodies (ABO2), anti-AB antibodies (ABO3), anti-D antibodies (RH1), anti-C antibodies (RH2), anti-c antibodies (RH4), anti-E antibodies (RH3), anti-e antibodies (RH5), anti-K antibodies (KEL1), anti-k antibodies (KEL2), anti-Kpb antibodies (KEL4), anti-Fya antibodies (FY1), anti-Fyb antibodies (FY2), anti-Jka antibodies (JK1), anti-Jkb antibodies (JK2), anti-S antibodies (MNS3), anti-s antibodies (MNS4), anti-Lea antibodies (LE1), anti-Leb antibodies (LE2), anti-M antibodies (MNS1), anti-N antibodies (MNS2), anti-P1 antibodies, anti-Kpa antibodies (KEL3), anti-Lua antibodies (LU1), anti-Lub antibodies (LU2), anti-Cw antibodies (RH8).

5 . The in vitro detection method as claimed in claim 1 , wherein the sample is a biological sample chosen from: a human serum, a human plasma and a human whole blood sample.

6 . The in vitro detection method as claimed in claim 1 , wherein at least two of the adsorption zones of the solid support are at least 100 μm apart from one another, and/or that said adsorption zones define an area of at least 10000 μm 2 .

7 . The in vitro detection method as claimed in claim 1 , wherein said solid support is a plastic support, and said adsorption zones are hydrophilic.

8 . The in vitro detection method as claimed in claim 1 , wherein said plurality of defined adsorption zones comprise a plane that is inclined relative to the rest of all or a portion of said solid support.

9 . The in vitro detection method as claimed in claim 1 , wherein the antibodies or antibody fragments capable of binding the antigenic determinants are noncovalently bonded to the defined adsorption zones.

10 . The in vitro detection method as claimed in claim 1 , wherein the adsorption zones of the solid support are functionalized with one or more bonding polymers comprising a polysaccharide backbone provided:

with aromatic groups of the form —X—CONH-Z, where X represents a substituted or unsubstituted, linear or branched alkyl chain comprising from 1 to 6 carbon atoms, and Z represents an aryl function; and/or

with carboxylic acid groups of the form —X—COOH, where X represents a substituted or unsubstituted, linear or branched alkyl chain comprising from 1 to 6 carbon atoms.

11 . The in vitro detection method as claimed in claim 1 , wherein said solid support is functionalized with one or more bonding polymers comprising one or more groups that are positively charged at the pH of said reaction mixture.

12 . The in vitro detection method as claimed in claim 1 , wherein the presence or absence of a hemagglutination reaction on said adsorption zone is determined by comparison with a distinct reference zone of said solid support.

13 . The in vitro detection method as claimed in claim 1 , wherein the determining step c) is carried out after a step of sedimenting said reaction mixture on said solid support.

14 . The in vitro detection method as claimed in claim 1 , wherein the determining step c) is carried out after a step of centrifuging said solid support.

15 . The in vitro detection method as claimed in claim 1 , wherein the sample is a plasma sample.